SBSimon Bannison Bani

Simon Bannison Bani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Bannison Bani has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Highly Active Antiretroviral Treatment on Complete Blood Count Parameters

    by Simon Bannison Bani, William K. B. A. Owiredu, Christian Obirikorang, Samuel A. Sakyi, Kwabena O. Danquah, Lawrence Quaye, Yussif Adams, Peter Paul M. Dapare, Moses Banyeh, Barnabas B. N. Gandau

    Aim: This study assesses the effects of HAART on complete blood count parameters among HIV infected participants. Study Design: Case control study. Place and Methods: This study was conducted in Tamale, Ghana from August, 2016 to December, 2017. Methodology: A total of 300 HIV infected participants with ages ranging from 19–79 years, administered with HAART for at least 6 months were recruited. Pre-HAART administration (baseline) demographic and clinical information, with initial full blood count results were retrieved from the medical records of the participants. Post HAART administration blood sample (5mLs) was taken from each participant into an EDTA vacutainer tube and complete blood count (CBC) performed using URIT 5250 haematology analyser. Participants transfused with blood over the last 4 months were excluded from the study. Results: The study recorded significant decreases in WBC and Neutrophil (%) post HAART administration. Lymphocyte (%), Haemoglobin, Haematocrit, MCV, MCHC, RDW-SD were all significantly higher post HAART administration. Total Platelets count, MPV, PDW-SD, PCT and P-LCR were significantly lower post-HAART administration. A comparison of the effects of EFV and NVP administered with AZT/3TC backbone yielded the following results. The NVP group recorded a significantly higher HCT compared with the EFV group (p-0.0073). A significantly higher mean PCT, MPV, P-LCR, PLCC, PDW-SD were recorded in the EFV group compared to the NVP group respectively. Conclusion: The administration of HAART is associated with significant improvements in erythroid and lymphoid lineages, reduce anaemia, improves immunity and general patient well-being. NVP improve erythroid cell indices while EFV ameliorate platelet indices. HAART regimen should be chosen based on the pre-HAART laboratory tests conducted on the individual.

  • Open Access

    Association of Single Nucleotide Polymorphisms with Dyslipidemia in Antiretroviral Exposed HIV Patients in a Ghanaian population

    by Christian Obirikorang, Emmanuel Acheampong, Lawrence Quaye, Joseph Yorke, Ernestine Kubi Amos-Abanyie, Priscilla Abena Akyaw, Enoch Odame Anto, Simon Bannison Bani, Evans Adu Asamoah, Emmanuella Nsenbah Batu

    Dyslipidemia is a potential complication of long-term usage of antiretroviral therapy (ART) and also known to be associated with genetic factors. The host genetic variants associated with dyslipidemia in HIV patients on ART in Ghana have not been fully explored. The study constituted a total of 289 HIV-infected patients on stable ART for at least a year and 85 aged matched apparently healthy control subjects with no history of HIV and dyslipidemia. Fasting blood was collected into EDTA tube for lipids measurements. Lipid profiles were determined as a measure of dyslipidemia. HIV-infected patients were categorized into two groups; those with dyslipidemia(HIV - Dys + ) (n=90; 31.1%) and without dyslipidemia (n=199; 68.9%) based on the NCEP-ATP III criteria. Four candidate single nucleotide polymorphisms (SNPs) genes (ABCA1-rs2066714, LDLR-rs6511720, APOA5-rs662799 and DSCAML1-rs10892151) were determined. Genotyping was performed on isolated genomic DNA of study participants using PCR followed by a multiplex Ligation Detection Reaction (LDR). The percentage of the population who had the rare homozygote alleles for rs6511720 (T/T), rs2066714 (G/G), and rs10892151 (T/T) and rs662799 (G/G) among HIV + Dys + subjects were 5.5%, 14.4%, 6.6% and 10.0%; 2.0% 9.1%, 6.5% and 4.0% among HIV + Dys - subjects while 3.5%, 4.7%, 4.7% and 2.4% were observed in HIV - Dys - subjects. Statistically significant difference in genotypic prevalence of APOA5 polymorphisms was observed among different groups (p=0.0196). Compared to the AA genotype of the APOA5 polymorphisms, individuals with the rare homozygote genotype [aOR =4.01, 95%CI(1.57-22.39), p=0.004] were significantly more likely to develop dyslipidemia after controlling for age, gender, treatment duration and CD4 counts among the HIV + Dys + subjects. There was also a significant associated between GG genotype of ABCA1 and dyslipidemia [aOR =3.29, 95% (1.08 −12.43); p=0.042]. Individuals with the rare homozygote variant (GG) of APOA5 (rs662799) were significantly associated with increased likelihood of developing dyslipidemia [OR =2.24, 95% CI (1.20 −6.83); p=0.0370] holding other variables constant in the HIV + Dys - subjects. Our data accentuate the presence of SNPs in four candidate genes and its association with dyslipidemia among HIV patients exposed to ART in the Ghanaian population especially variants in APOA5-rs662799 ABCA1-rs2066714 respectively. These findings provide baseline information that necessitates a pre-symptomatic strategy for monitoring dyslipidemia in ART-treated HIV patients. There is a need for longitudinal studies to validate a comprehensive number of SNPs and its association with dyslipidemia.